欧洲项目旨在管理检疫性有害生物。

华威大学牵头开展的“植物保护棱镜”(PhytoPRISM)项目,是欧盟“地平线欧洲”计划的一部分,专注于农产品和林业供应链中的病虫害风险管理。该项目已获得欧盟近600万欧元的资助,计划于2026年9月1日启动,2030年8月31日结束。

Nestlé Taps Precision-Fermented Donkey Milk to Make Whey Protein Without Dairy Allergens

Could donkey milk inspire the future of nutrition?Nestlé seems to think so, having filed a patent application to produce infant formula and food products using recombinant donkey whey protein.

Ahead of Ingredion Aquisition, Tate & Lyle Doubles Down on Cell-Cultured Sugar Alternatives

British ingredient giant Tate & Lyle has broadened its ongoing collaboration with Canadian plant cell culture company BioHarvest Sciences to develop next-gen sugar substitutes.

全新一代双导杀菌修复剂——亿嘉金朝颜:作物健康的″防护盾″+″修复剂″

作物病害反复、病斑难控?想防病又提质,选对药剂是关键!亿嘉集团全新一代双导杀菌修复剂 —— 亿嘉金朝颜,杀菌+营养黄金组合,协同增效,杀菌快、防护久、修复强,守护作物全程健康!

科迪华新型除草剂氟氯吡啶酯在中国登记扩展至冬油菜田

世界农化网中文网报道:2026年4月17日,科迪华农业科技有限责任公司新登记的58克/升氨氯吡·氟氯吡乳油(氨氯吡啶酸48克/升+氟氯吡啶酯10克/升)产品正式获批登记,登记作物/场所和防治对象为冬油菜田一年生阔叶杂草。这是氟氯吡啶酯首次在中国将登记从冬小麦田、小麦田、非耕地拓展至冬油菜田。

山东沾化永浩拟建年产2000吨砜吡草唑合成中间体生产线

世界农化网中文网报道:近日,山东沾化永浩医药科技有限公司年产2000吨5-羟基-1-甲基-3-三氟甲基-1H-吡唑项目环境影响评价第一次公众参与公告。

面积扩大、利润承压:巴西农业投入品市场预计将回升至550亿美元

世界农化网中文网报道:巴西一家农业咨询机构最新预测显示,2026/27作物季,巴西农业投入品行业市场规模有望回升至3000亿雷亚尔(约合550亿美元),同比增长8%,结束了过去四年的行业调整期。这一数字已接近2022/23季创下的3140亿雷亚尔历史峰值。该机构分析师指出,当前复苏的市场条件与当年不同——供应链库存已恢复至更平衡的水平,制造商和经销商能够在更健康的定价结构下运营。

江西众和生物在巴西取得丁噻隆原药登记证

世界农化网中文网报道:近日,江西众和集团旗下公司江西众和生物科技有限公司成功获得公司首张巴西登记证——丁噻隆(Tebuthiuron)98% TC。

V-Label Latam and Fundación Veg to Exhibit at Alimentec as Vegan Certification Gains Ground in Colombia

Fundación Veg and its certification arm V-Label Latam will be present at Alimentec, the biennial food and beverage trade fair held at Corferias in Bogotá, Colombia, from 9 to 12 June 2026. The two organizations will share a stand in Hall 6, Level 1, Booth 508, where they plan to meet food and beverage companies interested in vegan certification and related market opportunities.

Roche bets on BTK degradation in $2.3bn Nurix deal

Under the agreement, Nurix will receive US$700m upfront and could earn development, regulatory and sales milestones bringing the total potential value to US$2.3bn. The partners will share development costs, with Roche funding 60% and Nurix 40%. In the US, the companies will split profits and losses equally and co-commercialise the drug, while Roche will take responsibility for commercialisation outside the US, paying Nurix tiered royalties in the low- to high-teens. The transaction is expected to close in Q3/2026, subject to customary conditions.